GT Biopharma, Inc. (NASDAQ:GTBP) Sees Significant Decline in Short Interest

GT Biopharma, Inc. (NASDAQ:GTBP) saw a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 2,089,377 shares, a drop of 20.5% from the February 12th total of 2,629,402 shares. Approximately 20.3% of the company’s shares are sold short. Based on an average daily trading volume, of 923,696 shares, the days-to-cover ratio is currently 2.3 days. Based on an average daily trading volume, of 923,696 shares, the days-to-cover ratio is currently 2.3 days. Approximately 20.3% of the company’s shares are sold short.

Institutional Trading of GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC purchased a new position in GT Biopharma, Inc. (NASDAQ:GTBP) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned 0.47% of GT Biopharma at the end of the most recent reporting period. 8.15% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of GT Biopharma in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, GT Biopharma presently has a consensus rating of “Sell”.

GT Biopharma Trading Up 2.2%

Shares of NASDAQ GTBP traded up $0.01 during midday trading on Tuesday, hitting $0.43. The company’s stock had a trading volume of 391,347 shares, compared to its average volume of 1,284,346. GT Biopharma has a 12-month low of $0.39 and a 12-month high of $3.85. The firm has a market cap of $4.62 million, a P/E ratio of -0.07 and a beta of 1.29. The business’s 50 day moving average is $0.55 and its two-hundred day moving average is $0.67.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).